Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LuCarbo - a Phase 1a/1b Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

NCT06303713 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT06303713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06303713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LuCarbo - a Phase 1a/1b Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 22, 2024
Completion date
March 19, 2027
Enrollment
37 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer, metastatic prostate cancer, prostate cancer